Novo Nordisk A-S (Class B)

2024. szept. 23. 19:26 UTC

Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment

2024. nov. 3. 23:34 UTC

Stocks Poised for Lower Open -- Barrons.com

2024. okt. 31. 17:30 UTC

Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next. -- Barrons.com

2024. okt. 30. 16:28 UTC

Eli Lilly Stock Plummets As Zepbound, Mounjaro Sales Miss Estimates -- Barrons.com

2024. okt. 30. 15:46 UTC

Eli Lilly Stock Plummets As Zepbound, Mounjaro Sales Miss Estimates -- Barrons.com

2024. okt. 30. 13:54 UTC

Eli Lilly Stock Plummets As Zepbound, Mounjaro Sales Miss Estimates -- Barrons.com

2024. okt. 26. 11:00 UTC

Heard on the Street: Pfizer's Activist Battle Might Fizzle -- but Its Stock Probably Won't -- WSJ

2024. okt. 25. 09:30 UTC

Big Food Is Learning to Love Weight-Loss Drugs -- Heard on the Street -- WSJ

2024. okt. 4. 12:01 UTC

As Weight-Loss Drugs Battle, Upstart Viking -2-

2024. okt. 4. 12:01 UTC

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

2024. okt. 3. 14:45 UTC

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

2024. okt. 3. 13:12 UTC

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

2024. okt. 3. 12:51 UTC

Novo Nordisk's Weight-Loss Jab Trial Will Be Defining -- Market Talk

2024. okt. 2. 13:48 UTC

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com

2024. okt. 2. 12:28 UTC

Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk

2024. okt. 2. 09:00 UTC

Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk

2024. szept. 26. 13:15 UTC

Novo Nordisk's Share Price Looks Capped Ahead of New Drug Data -- Market Talk

2024. szept. 26. 11:51 UTC

Novo Nordisk Senate Hearing Removes a Share Overhang -- Market Talk

2024. szept. 23. 10:37 UTC

Fed Uncertainty Is History. Now Markets Need to Brace for Election Volatility. -- Barrons.com

2024. szept. 23. 10:37 UTC

Fed Uncertainty Is History. Now Markets Need to -2-

2024. szept. 20. 16:30 UTC

'Knee-Jerk' Corbus Selloff Seen as Buying Opportunity -- Market Talk

2024. szept. 20. 13:55 UTC

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

2024. szept. 20. 12:46 UTC

Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

2024. szept. 20. 09:30 UTC

The Price War in Weight-Loss Drugs Is Here -- WSJ

2024. szept. 12. 13:00 UTC

Senators Target Influencers, Telehealth Firms for Misleading Weight-Loss and Other Drug Promotion -- WSJ

2024. szept. 12. 11:45 UTC

Novo Nordisk's Obesity Pill Data Confirm Investor Optimism -- Market Talk

2024. szept. 12. 10:30 UTC

Novo Nordisk's Amycretin Obesity Pill Slightly Disappoints on Safety -- Market Talk

2024. szept. 11. 12:08 UTC

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids -- Barrons.com

2024. szept. 9. 07:56 UTC

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

2024. szept. 3. 11:09 UTC

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com